NEW YORK, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Microchip Technology Inc. (NASDAQGS: MCHP)
Class Period: March 2, 2018 - August 9, 2018
Lead Plaintiff Deadline: November 16, 2018
Join the action: https://www.zlk.com/pslra-1/microchip-technology-inc-loss-form?wire=3

About the lawsuit: Microchip Technology Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) Microsemi’s financial performance was underperforming Microchip’s expectations; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, including positive statements about Microsemi, were materially misleading and/or lacked a reasonable basis.

To learn more about the Microchip Technology Inc. class action contact jlevi@levikorsinsky.com.

TG Therapeutics, Inc. (NASDAQCM: TGTX)
Class Period: June 4, 2018 - September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
Join the action: https://www.zlk.com/pslra-1/tg-therapeutics-inc-loss-form?wire=3

About the lawsuit: TG Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.

To learn more about the TG Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.

Stitch Fix, Inc. (NASDAQ: SFIX)
Class Period: June 8, 2018 - October 1, 2018
Lead Plaintiff Deadline: December 10, 2018
Join the action: https://www.zlk.com/pslra-1/stitch-fix-inc-loss-form?wire=3

About the lawsuit: Throughout the class period, Stitch Fix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Stitch Fix’s active client growth had slowed to a crawl; (2) Stitch Fix had completely shut down its television advertising campaign for 10 of the 13 weeks in fourth quarter 2018, dramatically decreasing the number of new active client additions; and (3) as a result, the Company’s current business metrics and financial prospects were not as strong as it had led the market to believe during the Class Period.

To learn more about the Stitch Fix, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.